Title:Isorhamnetin: A Novel Natural Product Beneficial for Cardiovascular Disease
Volume: 28
Issue: 31
Author(s): Wen-Qing Li, Jing Li, Wen-Xiu Liu, Liu-Jun Wu, Jun-Yuan Qin, Zi-Wei Lin, Xin-Yu Liu, Shi-Yan Luo, Qing-Hua Wu*, Xiao-Fang Xie*Cheng Peng*
Affiliation:
- State Key Laboratory of Traditional Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
- State Key Laboratory of Traditional Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
- State Key Laboratory of Traditional Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
Keywords:
Isorhamnetin, cardiovascular disease, phytopharmacology, pharmacokinetics, pharmacological effects, traditional application, toxicity.
Abstract: Cardiovascular disease (CVD) has become a severe threat to human beings with increasing morbidity
and mortality. Isorhamnetin (Iso) shows multiple bioactivities, especially in the cardiovascular system. A
literature retrieval strategy was conducted in databases of PubMed, GeenMedical, Sci-Hub, Web of Science,
China National Knowledge Infrastructure (CNKI), and Baidu Scholar, with keywords defined as: “Isorhamnetin”,
“cardiovascular diseases”, “pharmacological effects”, “phytochemistry”, “pharmacokinetics”, “clinical application”
and “toxicity”. The language is restricted to Chinese and English, and publish date ranges from January,
2011 to September, 2021. So far, Iso has been isolated and identified from several natural medicines, including
Hippophae rhamnoides L., Ginkgo biloba L. and Typha angustifolia L., etc. The effects of Iso on CVD are
pharmacological, including anti-atherosclerosis, reducing blood fat, anti-inflammation, antioxidation, endothelial
protection, antithrombosis, antiplatelet aggregation, myocardial protection, and anti-hypertension. Iso could
inhibit the activities of CYPs in liver microsomes and suppress hepatocyte injury in vitro. However, no toxicity
was observed in vivo. Taken together, Iso has a wide range of positive effects on CVD with safe and multiple
pharmacological activities on the cardiovascular system and may be an ideal candidate drug for the prevention
and treatment of CVD. Therefore, further studies, especially on its clinic use, need to be conducted. The present
review summarizes the recent progress in phytochemistry, pharmacology, and mechanisms of action and provides
a reference for future studies on Iso.